Identifying biomarkers for treatment response and side effects of immune checkpoint inhibitors in cancer therapy
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
This study is looking at how we can better track the effectiveness and side effects of new cancer treatments called immune checkpoint inhibitors by using simple tests on patient samples, so we can help cancer patients manage their treatment more easily and improve their overall care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10462570 on NIH RePORTER |
What this research studies
This research investigates how immune checkpoint inhibitors, which are a new class of cancer treatments, can be monitored for their effectiveness and potential side effects through specific biomarkers. By focusing on patients receiving these therapies, the study aims to identify non-invasive methods to track treatment responses and adverse events in real-time. This could help in managing side effects more effectively and improving overall treatment outcomes for cancer patients. The research involves analyzing patient samples and clinical data to establish these biomarkers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced melanoma or other cancers being treated with immune checkpoint inhibitors.
Not a fit: Patients who are not receiving immune checkpoint inhibitors or those with early-stage cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of cancer treatment side effects and improved outcomes for patients undergoing immune checkpoint inhibitor therapy.
How similar studies have performed: Previous research has shown promising results in identifying biomarkers for cancer treatments, indicating that this approach has potential for success.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Wellstein, Anton — Georgetown University
- Study coordinator: Wellstein, Anton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.